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	 A	new	series	of	aryl	 clonazepam	derivatives	 (11‐16)	have	been	synthesized	by	employing
Suzuki	 Cross‐coupling	 reaction,	 which	 includes	 the	 reaction	 of	 clonazepam	 with	 suitable
derivative	boronic	acid	at	the	presence	of	Pd(PPh3)4	as	catalyst,	and	Na2CO3	as	a	base.	The
structures	 of	 the	 newly	 synthesized	 compounds	 were	 assigned	 by	 1H,	 13C	 and	 2D	 NMR
spectroscopic	techniques.	
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1.	Introduction	
	
Benzodiazepine	 (BDZs)	 derivatives	 are	 considered	 the	
most	important	sedatives	and	hypnotic	drugs	due	to	their	high	
therapeutic	 index	 number.	 On	 the	 other	 hand,	 BDZs	 have	
minor	 side	effects	on	 cardiovascular	 and	 respiratory	 systems	
due	 to	 the	 fact	 that	 there	 is	 no	 interaction	between	 the	drug	
and	 liver	 microsomal	 enzyme.	 All	 compounds	 of	 this	 group	
increase	onset	of	sleep	and	hence	increase	total	sleeping	time	
[1‐3].	
Benzodiazepine,	 if	 taken	 in	 low	 dose,	 produce	 relaxation	
mode	 with	 no	 evident	 effect	 on	 patients’	 physical	 activities.	
The	drugs	are	divided	into	two	groups	based	on	their	half‐life:	
long	term	benzodiazepines	such	as	diazepam,	flurazepam,	and	
short	 term	 lorazepam,	 oxazepam	 [4,5].	 Mechanism	 of	 action	
act	 on	 mide‐brain	 ascending	 reticular	 formation	 and	 limbic	
system.	 This	 chemical	 reaction	 stimulates	 gamma‐amino‐
butyric	acid	(GABA)	ergic	neurotransmission,	which	activates	
of	 GABA	 receptors	 which	 in	 turn	 leads	 to	 Cl	 ionophore	
complex	 and	 increases	 the	 opening	 of	 the	 Cl	 channel,	
Therefore	 the	 increase	of	 Cl	 conduction	will	 lead	 to	decrease	
activation	region	of	central	nervous	system	[6,7].	Clonazepam	
is	considered	one	of	long	acting	benzodiazepine	drugs	[8].	The	
seven	 amino	 ring	 (Diazepin	 ring)	 is	 vital	 for	 its	 biding	 with	
BDZs	 site	 [9].	 The	 lipophilic	 properties	 of	 BDZs	 play	 an	
important	role	 in	metabolism,	so	reach	to	brain	through	pass	
blood	brain	barrier	and	high	interact	with	receptor.	There	are	
many	 side	 effects	 to	 the	 drug,	 most	 important	 of	 all,	 is	
addiction	 to	 the	drug	which	occurs	over	a	 long	 term	used,	as	
well	 as	 deformation	 of	 the	 foetus	 in	 pregnant	 women	 [10].	
Clonazepam	 is	 usually	 prescribed	 as	 control	 drug	 to	 acute	
cases	 of	 epilepsy	 and	 it	 is	 very	 effective	 in	 controlling	 non‐
convulsive	 cases	 of	 epilepticus	 [11].	 The	 following	 drugs:	
erythromycin,	 clarithromycin,	 ritonavir,	 itraconazole,	 ketoco‐
nazole,	 nefazodone,	 and	 grapefruit	 juice	 are	 inhibitors	 of	
CYP3A4,	 an	 enzyme	 that	 is	 responsible	 of	metabolism	 of	 the	
BDZs	in	the	liver,	which	rise	the	half‐life	and	toxicity	[12].	
Researchers	 have	 given	 immense	 attention	 to	 studies	 of	
benzodiazepine	 derivatives	 for	 its	 property	 of	 medical	 and	
biological	 activities,	 some	 of	 which	 have	 been	 used	 as	
antitumor	 drugs	 [13],	 antagonists	 of	 schistosomicidal	 [14],	
anti‐HIV	 [15],	 antagonists	 for	 the	 Bradykinin	 [16],	 anti‐
arrhythmic	 agents	 [17],	 cholecystokinin	 receptor	 agonists	
[18],	 and	 antimalaria	 [19].	 Recent	 studies	 have	 shown	 that	
some	BDZs	compounds	have	been	synthesized	and	the	results	
have	presented	the	important	role	of	the	drugs	as	therapeutic	
drugs	used	specifically	 as	 anti‐hepatitis	B	virus	 [20].	Anderw	
et	al.	[21]	have	prepared	compound	1	(Figure	1)	using	Suzuki	
coupling	 reaction	 under	 standard	 aqueous	 conditions	 and	
conceder	it	a	new	method	to	prepared	1,4‐benzodiazepines.	In	
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2003,	Nadin	et	al.	[22]	synthesized	BDZs	compound	2	(Figure	
1)	via	Suzuki	coupling	reaction	as	a	vital	stage	for	synthesis	of	
the	active	compound	3	 (Figure	1)	as	γ‐secretase	 inhibitor	 for	
the	 handling	 of	 case	 of	 Alzheimer.	 In	 continuation	 of	 our	
program	on	the	synthesis	of	BDZs	derivatives,	we	investigated	
the	 synthesis	 of	new	derivatives	 of	 arylclonazepm	via	 Suzuki	
Cross‐coupling	reaction	[23,24].	
	
 
	
Figure	1.	Some	benzodiazepine	derivatives.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
Melting	 points	 are	 uncorrected	 and	were	measured	 on	 a	
Büchi	melting	point	apparatus	B‐545	(Büchi	Labortechnik	AG,	
Switzerland).	NMR	data	were	 obtained	 on	 400	 and	600	MHz	
(1H)	and	150.91	MHz	(13C)	spectrometers	(Avance	III,	Bruker,	
Germany)	with	TMS	as	internal	standard	and	on	the	δ	scale	in	
ppm.	 Heteronuclear	 assignments	 were	 verified	 by	 1H,	 13C	
HMBC	 and	 1H,	 13C	 HSQC	 NMR	 experiments.	 Micro‐analytical	
data	 were	 obtained	 with	 a	 Vario,	 Elemental	 analyzer	
(Shimadzu,	Japan).	Analytical	silica	gel	TLC	plates	60F254	were	
purchased	 from	 Merck.	 All	 reagents	 were	 obtained	 from	
commercial	 suppliers	 and	 were	 used	 without	 further	
purification	[25].	
	
2.2.	General	procedure	for	the	synthesis	of	the	biaryl	
derivatives	of	clonazepam	via	Suzuki	Cross‐coupling	
reaction	(11‐16)	
	
To	 a	 solution	 of	 clonazepam	 (4)	 (60	 mg,	 0.20	 mmol)	 in	
mixture	 of	 chloroform	 (10	 mL)	 with	 MeOH	 (5	 mL),	 aryl	
boronic	 acid	 (0.2	 mmol)	 was	 added,	 then	 the	 mixture	 was	
stirred	 for	 15	 min	 at	 suitable	 temperature	 then	 adding	
Pd(0)(PPh3)4	(100	mg,	5	%mmol)	and	aqueous	solution	of	2	M	
sodium	 carbonate	 (5	 mL).	 The	 mixture	 was	 heated	 under	
reflux	 for	 12‐14	 h.	 After	 cooling	 phase,	 water	 (5	 mL)	 was	
added	and	the	mixture	was	partitioned	with	ethyl	acetate	(3	×	
10	mL)	and	the	combined	organic	extracts	which	were	washed	
with	 aqueous	 solution	 of	 5%	Na2CO3	 (3	 ×	 10	mL),	 and	 dried	
with	 sodium	 sulfate	 and	 then	 evaporated	 in	 vacuum.	 The	
residue	was	then	filtered	on	a	short	SiO2	column	using	hexane:	
ethyl	acetate	(3:2,	v:v)	as	eluent	to	get	the	desired	product	[26]	
(Scheme	1).	
5‐(4'‐(Methylthio)‐[1,1'‐biphenyl]‐2‐yl)‐7‐nitro‐3H‐benzo[e]	
[1,4]diazepin‐2‐ol	(11):	From	4‐methylthiophenyl	boronic	acid	
(80	mg).	 Yield:	 40	mg	 (67%)	 as	 a	 light	 brown	 powder.	M.p.:	
248‐250	 °C.	Rf	 :	 0.58.	 1H	NMR	 (600	MHz,	 DMSO‐d6,	 δ,	 ppm):	
2.38	(s,	3H,	SMe),	7.00	(br	s.,	1H,	Harom.‐6'),	7.43	(m,	4H,	Harom.‐
5'	 +	 H‐3(CH2)+	 Harom.‐6),	 7.56	 (m,	 3H,	 Harom.‐9	 +	 Harom.‐3"	 +	
Harom.‐5''),	7.62	 (m,	4	H,	Harom.‐2"	+	Harom.‐6"+Harom.‐4'	+	Harom.‐
3'),	7.98	 (d,	1H,	 J8,9	=	8.6	Hz,	Harom.‐8).	 13C	NMR	(150.91	MHz,	
DMSO‐d6,	 δ,	 ppm):	 15.2	 (SMe),	 49.7	 (C‐3),	 124.9	 (Carom.‐3'),	
126.9	 (Carom.‐9),	127.2	 (Carom.‐2"	+	Carom.‐6"),	127.7	 (Carom.‐3''	+	
Carom.‐5"),	129.2‐129.7	 (Carom.‐6+Carom.‐5'+Carom.‐8),	131.9‐132.0	
(Carom.‐2'+	 Carom.‐6'),	 132.5	 (Carom.‐4'),	 135.3	 (Carom.‐5a),	 137.	 8	
(Carom.‐4"),	 141.1	 (Carom.‐1'	 +	 Carom.‐1"),	 147.8	 (Carom.‐7),	 156.8	
(Carom.‐9a),	 162.8	 (C‐2),	 167.65	 (C‐5).	 Anal.	 calcd.	 for	
C22H17N3O3S:	 C,	 65.49;	 H,	 4.25;	 N,	 10.42.	 Found:	 C,	 65.22;	 H,	
4.11;	N,	10.20%.	
2'‐(2‐Hydroxy‐7‐nitro‐3H‐benzo[e][1,	 4]diazepin‐5‐yl)‐bi	
phenyl‐3‐carbonitrile	 (12):	 From	 4‐cyanophenylboronic	 acid	
(80	mg).	Yield:	35	mg	 (58	%)	as	a	dark	brown	powder.	M.p.:	
264‐266	°C.	Rf:	50.	1H	NMR	(600	MHz,	DMSO‐d6,	δ,	ppm):	7.00	
(br	 s,	 1H,	 Harom.‐6'),	 7.33‐7.56	 (m,	 4H,	 Harom.‐3'	 +	 H‐3(CH2)	 +	
Harom.‐6),	7.62‐7.64	(m,	3H,	Harom.‐9	+	Harom.‐4'+Harom.‐5'),	7.70‐
7.73	(m,	1H,	J	=	7.8	Hz,	Harom.‐5''),	7.86‐7.91	(d,	1H,	J	=	7.8	Hz,	
Harom.‐6''),	8.07‐8.14	(m,	1H,	Harom.‐8),	8.30	(br	s,	1H,	Harom.‐2"),	
8.43	 (br	s,	1H,	Harom.‐4").	 13	C	NMR	(150.91	MHz,	DMSO‐d6,	 δ,	
ppm):	49.8	(C‐3),	112.7	(CN),	119.1	(Carom.‐3"),	121.2	(Carom.‐3'),	
129.1	 (Carom.‐9),	 129.2	 (Carom.‐6),	 129.3	 (Carom.‐5"),	 129.6	
(Carom.‐5'	 +	 Carom.‐8),	 129.8	 (Carom.‐2"),	 130.8	 (Carom.‐6'),	 131.9	
(Carom.‐4"),	 132.2	 (Carom.‐6"),	 132.4	 (Carom.‐4'),	 132.5	 (Carom.‐2'),	
135.3	 (Carom.‐5a),	141.1	 (Carom.‐1'	+	Carom.‐1"),	148.5	 (Carom.‐9a),	
156.8	 (Carom.‐7),	 162.8	 (C‐2),	 168.1	 (C‐5).	 Anal.	 calcd.	 for	
C22H14N4O3:	 C,	 69.10;	 H,	 3.69;	 N,	 14.65.	 Found:	 C,	 68.82;	 H,	
3.54;	N,	14.41%.	
5‐(4'‐Fluoro‐biphenyl‐2‐yl)‐7‐nitro‐3H‐benzo[e][1,	 4]	 diaze	
pin‐2‐ol	(13):	From	4‐fluorophenylboronic	acid	(80	mg).	Yield:	
33	mg	 (55%)	 as	 a	 dark	 brown	powder.	M.p.:	 261‐263	 °C.	Rf:	
0.67.	1H	NMR	(600	MHz,	DMSO‐d6,	δ,	ppm):	6.52	(br	s,	1H,	OH),	
7.00	 (br	 s,	 1H,	 Harom.‐6'),	 7.12‐7.14	 (dd,	 1H,	 J	 =	 7.9,1.8	 Hz,	
Harom.‐3'),	 7.32‐7.45	 (m,	 7H,	 Harom.‐2"	 +	 Harom.‐6"	 +	 Harom.‐3"	 +	
Harom.‐5"	 +	 H‐3(CH2)+Harom.‐6),	 7.55‐7.65	 (m,	 3H,	 Harom.‐9	 +	
Harom.‐4',	Harom.‐5'),	 8.09	 (br	 s,	 1H,	Harom.‐8).	 13	C	NMR	 (150.91	
MHz,	 DMSO‐d6,	 δ,	 ppm):49.5	 (C‐3),	 114.6‐114.8	 (Carom.‐
3"+Carom.‐5"),	 122.2	 (Carom.‐3'),	 127.7	 (Carom.‐9),	 129.19‐129.76	
(Carom.‐6	+	Carom.‐5'+Carom.‐8),	130.8	(Carom.‐2"	+	Carom.‐6"),	131.9‐
132.0	 (Carom.‐6'+	 Carom.‐2'),	 132.6	 (Carom.‐4'),	 135.3	 (Carom.‐5a),	
141.04	 (Carom.‐1'+Carom.‐1"),	 147.0	 (Carom.‐7),	 156.8	 (Carom.‐9a),	
159.0‐161.2	 (Carom.‐4"),	 162.81	 (C‐2),	 168.3	 (C‐5).	Anal.	 calcd.	
for	C22H14FN3O3:	C,	67.20;	H,	3.76;	N,	11.19.	Found:	C,	66.95;	H,	
3.59;	N,	10.98%.	
7‐Nitro‐5‐(4'‐trimethylsilanyl‐biphenyl‐2‐yl)‐3H‐benzo	 [e]	
[1,4]diazepin‐2‐ol	 (14):	 Form	 4‐(trimethylsilyl)phenylboronic	
acid	 (90	mg).	 Yield:	 39	mg	 (65%)	 as	 a	 dark	 brown	 powder.	
M.p.:	 246‐248	 °C.	 Rf:	 0.54.	 1H	 NMR	 (600	 MHz,	 DMSO‐d6,	 δ,	
ppm):	0.18‐0.27	(m,	9H,	SiMe3),	7.00	(br	s,	1H,	Harom.‐6'),	7.31‐
7.35	 (dd,	 1H,	 J	 =	 7.8,	 1.9	 Hz,	 Harom.‐6"),	 7.41‐7.44	 (m,	 4H,	
Harom.‐5'	 +	 H‐3(CH2)	 	 +Harom.‐6),	 7.47‐7.48	 (d,	 1H,	 J	 =	 7.8	 Hz,	
Harom.‐3"),	7.54‐7.57	(dd,	1H,	J=	8.1,	1.8	Hz,	Harom.‐9),	7.60‐7.65	
(m,	3H,	Harom.‐4'	+	Harom.‐3'	+	Harom.‐5"),	7.75‐7.77	(d,	1H,	J	=	7.8	
Hz,	Harom.‐2"),	8.03	(br	s,	1H,	Harom.‐8).	13	C	NMR	(150.91	MHz,	
DMSO‐d6,	 δ,	 ppm):	 0.45	 (SiMe3),	 49.4	 (C‐3),	 119.0	 (Carom.‐3')	
126.8	 (Carom.‐3"	 +	 Carom.‐5"),	 127.9	 (Carom.‐2"+Carom.‐6"),	 129.4‐
129.9	 (Carom.‐9	 +	 Carom.‐6	 +	 Carom.‐5'+Carom.‐8),	 130.9	 (Carom.‐6'),	
132.2	 (Carom.‐4'),	 132.7	 (Carom.‐2'),	 135.7	 (Carom.‐5a),	 141.3	
(Carom.‐4"),	 142.4	 (Carom.‐1'	 +	 Carom.‐1"),	 148.5	 (Carom.‐7),	 156.9	
(Carom.‐9a),	 162.7	 (C‐2),	 168.3	 (C‐5).	 Anal.	 calcd.	 for	
C24H23N3O3Si:	 C,	 67.11;	 H,	 5.40;	 N,	 9.78.	 Found:	 C,	 66.90;	 H,	
5.38;	N,	9.52%.	
5‐(3',4'‐Dimethoxy‐[1,1'‐biphenyl]‐2‐yl)‐7‐nitro‐3H‐benzo[e]	
[1,4]diazepin‐2‐ol	 (15):	 Form	 3,4‐dimethoxyphenylboronic	
acid	(80	mg).	Yield:	38	mg	(63%)	as	a	brown	red	powder.	M.p.:	
241‐243	 °C.	Rf	 :	 0.54.	 1H	 NMR	 (600	MHz,	 DMSO‐d6,	 δ,	 ppm):	
3.78	(d,	3H,	OMe),	3.84	(d,	3H,	OMe),	6.99‐7.01	(m,	2H,	Harom.‐
2"+Harom.‐6'),	 7.14‐7.16	 (dd,	 1H,	 J=	7.8,	 1.8	Hz,	Harom.‐3'),	 7.17	
(d,	1H,	J	=	1.8	Hz,	Harom.‐5"),	7.35‐7.36	(m,	1H,	Harom.‐6"),	7.41‐
7.44	 (m,	 4H,	 Harom.‐5'+H‐3(CH2)+Harom.‐6),	 7.54‐7.56	 (dd,	 1H,	
Harom.‐9),	 7.61‐7.63	 (m,	1H,	Harom.‐4'),	 7.87	 (br	 s,	1H,	Harom.‐8).	
13C	 NMR	 (150.91	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 50.7	 (C‐3),	 56.1	
(2×OMe),	 110.9	 (Carom.‐5"),	 112.7	 (Carom.‐2"),	 119.0	 (Carom.‐3'),	
127.7	(Carom.‐6"),	127.2	(Carom.‐9),	129.2	(Carom.‐6),	129.6	(Carom.‐
5'),	 129.8	 (Carom.‐8'),	 130.8	 (Carom.‐6'),	 131.9	 (Carom.‐4'),	 131.9	
(Carom.‐2'),	 135.3	 (Carom.‐5a),	 141.1	 (Carom.‐1'+Carom.‐1"),	 148.5	
(Carom.‐7),	 149.4	 (Carom.‐4"),	 151.0	 (Carom.‐3"),	 156.8	 (Carom.‐9a),	
162.8	(C‐2),	168.3	(C‐5).	Anal.	calcd.	 for	C23H19N3O5:	C,	66.18;	
H,	4.59;	N,	10.07.	Found:	C,	66.98;	H,	3.67;	N,	10.89%.	
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Scheme	1
	
	
2'‐(2‐Hydroxy‐7‐nitro‐3H‐benzo[e][1,	 4]diazepin‐5‐yl)‐5‐
nitro‐[1,1'‐biphenyl]‐3‐carboxylic	 acid	 (16):	 From	 3‐nitro‐5‐
nitrophenylboronic	 acid	 (90	 mg).	 Yield:	 39	 mg	 (65%)	 as	 a	
brown	powder.	M.p.:	258‐260	°C.	Rf	 :	0.55.	1H	NMR	(600	MHz,	
DMSO‐d6,	 δ,	 ppm):	 6.30	 (s,	 1H,	NH),	 6.62‐6.64	 (m,	 3H,	Harom.‐
3'+Harom.‐4'	+	Harom.‐5'),	6.99‐7.00	(d,	1H,	 J	=	7.8,	Hz,	Harom.‐6'),	
7.41‐7.43	(m,	3H,	H‐3(CH2)	+	Harom.‐9),	7.60‐7.63	(m,	2H,	Harom.‐
6+Harom.‐8),	8.51	(s,	1H,	Harom.‐4b),	8.61	(s,	1H,	‐Harom.‐6b),	8.66‐
8.67	 (s,	 1H,	Harom.‐2b),	 12.26	 (s,	 1H,	 CO2H).	 13C	NMR	 (150.91	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 49.8	 (C‐3),	 120.1	 (Carom.‐3'),	 120.8	
(Carom.‐4"),	 127.6	 (Carom.‐9),	 128.3	 (Carom.‐6),	 129.0	 (Carom.‐5'),	
129.3	 (Carom.‐8),	 130.03	 (Carom.‐6"),	 131.1	 (Carom.‐6'),	 133.44	
(Carom.‐2'+Carom.‐3"),	 134.2	 (Carom.‐4'),	 134.5	 (Carom.‐5a),	 141.0	
(Carom.‐1'+Carom.‐1"),	 147.5	 (Carom.‐7),	 148.2	 (Carom.‐3"),	 155.4	
(Carom.‐9a),	161.6	(C‐2),	168.1	(C‐5),	169.5	(CO2H).	Anal.	calcd.	
for	C22H14N4O7:	C,	59.20;	H,	3.16;	N,	12.55.	Found:	C,	58.98;	H,	
3.01;	N,	12.31%.	
	
3.	Results	and	discussion	
	
Suzuki	 Cross‐coupling	 reaction	 [24]	has	been	used	 in	 the	
preparation	of	new	clonazepam	analogues.	Thus,	treatment	of	
clonazepam	(4)	with	the	appropriate	arylboronic	acids	(e.g.:	4‐
methylsulfanylphenyl‐,	 3‐cyanophenyl‐,	 4‐fluorophenyl‐,	 4‐tri	
methylsilylphenyl‐,	 3,4‐dimethoxyphenyl‐,	 5‐nitro‐3‐carboxy	
phenyl	 boronic	 acid	 (5‐10)	 using	 palladium(0)	 tetrakis‐
triphenylphosphine	(Pd(0)(Ph3P)4)	and	sodium	bicarbonate	as	
catalyst	 in	 mix	 chloroform	 with	 MeOH	 as	 solvent	 afforded	
compound	11‐16	in	55‐67%	(Scheme	1).	
The	structure	of	 compounds	11‐16	were	assigned	on	 the	
basis	of	their	1H	and	13C	NMR	which	showed	similar	patterns	
of	aliphatic	proton	and	carbon	atoms	 .The	1H	NMR	spectra	of	
compound	 11‐16	 were	 characterized	 by	 the	 presence	 of	
additional	 aromatic	 protons	 and	 carbon	 atoms,	 indicative	 for	
arylation	 of	 clonazepam	 backbone.	 The	 aromatic	 proton	
appeared	 at	 the	 region	 δ	 6.62‐8.67	 ppm,	 the	 diazepine	 ring	
protons	(CH2)	appeared	at	δ	7.32‐7.56	ppm,	the	other	aliphatic	
protons	 and	 substituents	 have	 been	 fully	 identified	 (c.f.	
Experimental	 part).	 The	 compounds	 11‐16	 contain	 tauto‐
merism	 in	 amide	 bond	 so	 that	 appeared	 signal	 OH	 in	
compounds	 11‐15,	 while	 signal	 NH	 in	 compound	 16.	
Regarding	the	1H	NMR	to	see	the	OH	and	NH,	in	general,	the	1H	
NMR	spectra	of	some	compounds	do	not	show	the	OH	and	NH,	
either	they	appeared	under	the	other	signals	or	due	to	the	use	
of	DMSO‐d6	as	a	solvent.	
In	the	13C	NMR	spectra	of	compound	11‐16,	 the	aromatic	
carbon	 atoms	 appeared	 at	 δ	 110.9‐156.9	 ppm,	 the	 diazepine	
ring	 carbon	 atoms	 at	 δ	 49.42‐50.96	 ppm	 to	 C‐3,	 at	 δ	 161.6‐
162.8	 ppm	 to	 C‐2,	 at	 δ	 168.1‐168.3	 ppm	 to	 C‐5.	 The	 other	
aliphatic	 carbon	 atoms	 and	 subtituents	 have	 been	 fully	
analysed	(c.f.	Experimental	part).	However,	compound	11	has	
been	selected	for	further	NMR	experiments	[27‐29].	The	HSQC	
NMR	spectrum	[30]	of	compound	11	showed	 JC,H	correlations	
between	Harom.‐3’	 together	with	Harom.‐4’	 at	 the	 region	δ	7.61‐
7.63	ppm	and	C‐3’	 at	 δ	 124.9	ppm	as	well	 as	 C‐4’	 at	 δ	 132.4	
ppm.	Furthmore,	a	correlation	between	Harom.‐6’	at	δ	7.00	ppm	
and	C‐6’	at	δ	132.0	ppm	is	observed.	In	addition,	a	correlation	
between	H‐6	at	δ	7.42‐7.44	ppm	and	C‐6	at	the	region	δ	129.2‐
129.7	ppm	is	witnessed	(Figure	2).	
	
	
	
Figure	2.	JC,H	correlations	in	the	HSQC	NMR	spectrum	of	compound	11.	
	
In	the	gradient‐selected	HMBC	spectrum	[30]	of	compound	
11,	 C‐9a	 of	 the	 diazepin	 ring	 at	 δ	 156.8	 ppm	 showed	 a	 3JC,H	
coupling	 with	 H‐8	 of	 the	 same	 ring	 at	 δ	 7.98	 ppm.	 A	 3JC,H	
coupling	between	Carom.‐2’	at	δ	131.9‐132.0	ppm	and	Harom.‐6’’	
at	δ	7.62	ppm	was	observed.	Another	3JC,H	coupling	was	shown	
between	Carom.‐1’’	at	δ	141.1	ppm	and	Harom.‐3’	at	δ	7.62	ppm.	
The	 spectrum	 showed	 a	 2JC,H	 coupling	 between	 Carom.‐1’	 at	 δ	
141.1	ppm	and	Harom.‐6’	at	δ	131.9‐132.0	ppm	well	(Figure	3).	
	
	
	
Figure	3.	JC,H correlations	in	the	HMBC	NMR	spectrum	of	compound	11.
	
4.	Conclusion	
	
In	 conclusion,	 a	 new	 series	 of	 biaryl	 derivatives	 of	 aryl	
clonazepam	 by	 applying	 Suzuki	 Cross‐coupling	 reaction	 has	
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been	 described.	 All	 the	 compounds	 were	 assigned	 by	 their	
NMR	 spectra.	 The	 aim	 of	 synthesis	 of	 such	 compounds	 is	 to	
evaluate	 their	 antiviral	 and	 antitumor	 activity,	 which	 is	 in	
progress,	 since	 there	 is	 a	 lack	 in	 study	 of	 the	 potency	 of	 the	
related	analogues	of	diazepine	drugs.	
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